Advertisement


Johan F. Vansteenkiste, MD, PhD, on NSCLC: Immunotherapy and Targeted Treatments

ESMO 2018 Congress

Advertisement

Johan F. Vansteenkiste, MD, PhD, of Catholic University Leuven, summarizes a session he co-chaired that included discussion of translating advances in stage IV disease to nonmetastatic lung cancer, TKI approaches in early-stage disease, and integrating immunotherapy and TKIs in stage III disease management.



Related Videos

Bladder Cancer
Kidney Cancer
Immunotherapy

Cora N. Sternberg, MD, on Renal and Bladder Cancers: Focus on Immunotherapy

Cora N. Sternberg, MD, of San Camillo-Forlanini Hospital and the Israel Englander Institute of Precision Medicine at Weill Cornell, discusses results from the phase III CheckMate-0...

Skin Cancer

Alexander M.M. Eggermont, MD, PhD, on Melanoma: Advances in Adjuvant Therapy

Alexander M.M. Eggermont, MD, PhD, of Gustave Roussy, discusses findings from recent adjuvant trials in high-risk melanoma, and what the NCCN Guidelines recommend in light of such data as res...

Breast Cancer

Matthew J. Ellis, MB, BChir, PhD, on Breast Cancer: Neoadjuvant Endocrine Therapy

Matthew J. Ellis, MB, BChir, PhD, of the Baylor College of Medicine, discusses data on endocrine therapy alone or in combination with targeted treatments for postmenopausal women w...

Issues in Oncology
Immunotherapy
Symptom Management

Caroline Robert, MD, PhD, on Immunotherapy Toxicities: Expert Perspective

Caroline Robert, MD, PhD, of Gustave Roussy Cancer Centre, discusses managing toxicities of immunotherapy, including neurotoxicity, and treating beyond acute adverse events.

Bladder Cancer
Immunotherapy

Ronald de Wit, MD, PhD, on Bladder Cancer: Results From KEYNOTE-057

Ronald de Wit, MD, PhD, of the University Medical Center Rotterdam, discusses phase II findings on the efficacy of pembrolizumab in Bacillus Calmette Geurin–unresponsive bladder ca...

Advertisement

Advertisement



Advertisement